U.S. FDA approves landmark pancreatic cancer drug that's shown to improve survival
U.S. officials gave expedited approval to the first-of-a-kind pill, called daraxonrasib, which blocks a mutated protein that fuels tumour growth in more than 90% of pancreatic cancer cases. It's an approach that previously eluded drugmakers for decades.